CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Ocugen licenses OCU400 retinitis pigmentosa gene therapy rights to Roots Pharmaceutical in MENA region

By Public Technologies
  • Ocugen signed an exclusive MENA licensing deal with Roots Pharmaceutical for OCU400, its modifier gene therapy for retinitis pigmentosa.
  • Terms include an upfront license fee, up to $4 million in initial development payments, up to $255 million in sales milestones.
  • Ocugen will earn 22% royalties on OCU400 net sales in the region.
  • Commercial supply will be manufactured and supplied by Ocugen under a related supply agreement.
  • Phase 3 liMeliGhT topline data is expected in Q1 2027, ahead of planned U.S. and European filings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140630PRIMZONEFULLFEED9845309) on October 14, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk